Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Executive Summary
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
You may also be interested in...
Perrigo Primed For M&A; Sheds Elan Asset
The now Dublin-based private-label nutrition company is hoping to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.
Perrigo Primed For M&A; Sheds Elan Asset
The now Dublin-based private-label nutrition company is hoping to add to its specialty generics offerings and its “promotable” brands with tuck-in acquisitions.
2013 Deals Review Finds Spec Pharma, Bolt-Ons Dominated M&A
According to the Strategic Transactions database, 2013 saw 92 deals involving biopharma M&A completed or close to completion; the most active participants were specialty pharma companies, with only a handful of big pharmas committing to buying up assets.